Navigation Links
Optimer Pharmaceuticals and Cubist Pharmaceuticals Announce Collaboration to Co-Promote DIFICID™ (Fidaxomicin) for Clostridium difficile Infection in the United States
Date:4/6/2011

I, DIFICID was equally effective in clinical cure when compared to vancomycin, the only FDA approved product for CDI.  DIFICID also demonstrated statistically significant reduction in recurrences and an increase in global cure rate, defined as cure without recurrence. Importantly, DIFICID reduced the risk of recurrence by 47% compared to vancomycin. The New England Journal of Medicine has published results from the first Phase 3 trial in an article titled, "Fidaxomicin versus Vancomycin for Clostridium difficile Infection," which appeared in the February 3, 2011 issue.  Optimer filed a marketing application in the EU for DIFICID for the treatment of CDI and reducing risk of recurrence when used for treatment of initial CDI.  

About Clostridium difficile Infection (CDI)

Clostridium difficile infection (CDI), commonly referred to as "C. difficile" or "c-diff", has become a significant medical problem in hospitals, long-term care facilities, and in the community and is estimated to afflict more than 700,000 people each year in the U.S.  It is a serious illness resulting from infection of the inner lining of the colon by C. difficile bacteria, which produce toxins that cause inflammation of the colon, severe diarrhea and, in the most serious cases, death.  Patients typically develop CDI from the use of broad-spectrum antibiotics that disrupt normal gastrointestinal (gut) flora, thus allowing C. difficile bacteria to flourish and produce toxins.

Current therapeutic options for CDI include the off-label use of metronidazole and oral vancomycin, the latter being the only FDA-approved treatment.  However, approximately 20% to 30% of CDI patients who initially respond to these treatments experience a clinical recurrence following cessation of the CDI treatment.

Primary risk factors for CDI include broad-spectrum antibiotic use
'/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Optimer Announces that the U.S. Food and Drug Administrations Anti-Infective Drugs Advisory Committee Voted Unanimously to Recommend Approval of Novel Antibiotic Dificid™ for Treatment of Patients with Clostridium difficile infection (CDI)
2. Trading Halted Today in Optimer Pharmaceuticals Stock
3. Optimer Pharmaceuticals Announces Presentation at SHEA of Data Highlighting the Burden of Clostridium difficile Infection (CDI) in Hospital Patients
4. Optimer Pharmaceuticals Announces Presentation at Upcoming SHEA Annual Meeting Regarding Hospital CDI Patients at Risk of Recurrence and Mortality
5. Optimer Pharmaceuticals Announces Issuance of Key Patent Covering Fidaxomicin Methods of Use as a Treatment of Clostridium difficile infection
6. Optimer Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results
7. Optimer Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2010 Financial Results
8. Optimer Pharmaceuticals to Present at March 2011 Investor Conferences
9. Optimer Pharmaceuticals, Inc. Prices Public Offering of Common Stock
10. Optimer Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
11. Optimer Pharmaceuticals and Astellas Announce Collaboration to Commercialize Fidaxomicin for Clostridium difficile infection (CDI) in Europe and Certain Other Countries in Middle East, Africa and CIS
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/3/2015)... Sept. 3, 2015  Cipla, a global pharmaceutical company ... needs of all patients, today announced that its UK ... acquire two US-based companies, InvaGen Pharmaceuticals Inc., and Exelan ... conditions, is valued at $550 million and will be ... transactions is over $200 million for the year ended ...
(Date:9/3/2015)... Sept. 3, 2015 Report ... to that Market, its R&D and Sales Potentials ... future of cancer-treating medicines? Visiongain,s new report gives you revenue ... There you discover financial data, R&D trends, opportunities, interviews and ... our analysis you see forecasted sales to 2025 at overall ...
(Date:9/3/2015)... 3, 2015 About self-monitoring blood glucose ... home-based electronic device. It consists of a glucose ... glucose levels through radiowaves from the sensor to ... usage of self-monitoring blood glucose devices can improve ... undergo proper diabetes treatment. Technavio,s analysts ...
Breaking Medicine Technology:Cipla to acquire 100% of generic businesses in US for $550M 2Cipla to acquire 100% of generic businesses in US for $550M 3Cipla to acquire 100% of generic businesses in US for $550M 4Cipla to acquire 100% of generic businesses in US for $550M 5World Cancer-Treating Drugs Industry and Market: Companies, Therapies, R&D and Forecasts 2015-2025 2World Cancer-Treating Drugs Industry and Market: Companies, Therapies, R&D and Forecasts 2015-2025 3World Cancer-Treating Drugs Industry and Market: Companies, Therapies, R&D and Forecasts 2015-2025 4World Cancer-Treating Drugs Industry and Market: Companies, Therapies, R&D and Forecasts 2015-2025 5World Cancer-Treating Drugs Industry and Market: Companies, Therapies, R&D and Forecasts 2015-2025 6World Cancer-Treating Drugs Industry and Market: Companies, Therapies, R&D and Forecasts 2015-2025 7Global Self-monitoring Blood Glucose Devices Market 2015-2019 2
(Date:9/4/2015)... ... September 04, 2015 , ... ... separate “Partner of the Year” awards at this year’s Microsoft Worldwide Partner Conference ... 2015 “Partner of the Year” Award Winner for Data Platform services, the 2015 ...
(Date:9/4/2015)... (PRWEB) , ... September 04, 2015 , ... ... that CEREC technology is now available at CitiDent. CEREC is a newer method ... addition to saving time for patients by eliminating the need for multiple appointments, ...
(Date:9/4/2015)... ... , ... Mike Day, a former Navy SEAL who was shot 27 times ... in Kona on October 10th. , Mike is running the race to raise awareness ... the cutting-edge treatments that restore their quality of life. More than 300,000 ...
(Date:9/4/2015)... Pass, OR (PRWEB) , ... September 04, 2015 ... ... that markets a line of personal humidifying medical devices, announced its only mission ... climate, explains Bio-Logic Aqua® Research Founder Sharon Kleyne, body water evaporation is becoming ...
(Date:9/4/2015)... ... 2015 , ... The conference program for the upcoming Integrative ... 2015 at the Diplomat Resort & Spa has been announced and is available ... the top of their field and will be presenting sessions such as What ...
Breaking Medicine News(10 mins):Health News:Scalability Experts is Awarded Three Separate 2015 “Partner of the Year” Awards at Microsoft’s Worldwide Partner Conference 2Health News:Scalability Experts is Awarded Three Separate 2015 “Partner of the Year” Awards at Microsoft’s Worldwide Partner Conference 3Health News:Scalability Experts is Awarded Three Separate 2015 “Partner of the Year” Awards at Microsoft’s Worldwide Partner Conference 4Health News:San Francisco Dentist, Dr. Ben Amini, is Now Offering CEREC Technology at CitiDent 2Health News:Navy SEAL Shot 27 Times Competes in Ironman World Championship in Kona to Raise Money for Veteran's Suffering from TBI and PTSD 2Health News:Bio-Logic Aqua® Research Announces Water Life Science and Body Water Evaporation as Research Focus and Mission 2Health News:Bio-Logic Aqua® Research Announces Water Life Science and Body Water Evaporation as Research Focus and Mission 3Health News:Integrative Healthcare Symposium Focus On: The Microbiome Conference Program Announced 2
... (Nasdaq: ROCM ) today announced operating results for,its ... The Company reported 23% sales growth with record sales ... the fourth quarter of,last year, resulting from increases in ... reported net income of $733,000 or $.06 per,diluted share ...
... -- China Nepstar,Chain Drugstore Ltd. (NYSE: NPD ... chain in China based on the number of ... the Company,s initial,public offering ("IPO") have exercised their ... Shares ("ADSs") from the Company at,the IPO price ...
... /PRNewswire-FirstCall/ - NovaBay,Pharmaceuticals, Inc. (AMEX & TSX: NBY), ... targeting the,treatment or prevention of a wide range ... the third quarter ended September 30, 2007. ... 2007 was $1.6 million, or,$0.24 per share, as ...
... foods lowered odds up to 60%, study found , THURSDAY, ... of fish, omega-3 rich oils, fruits and vegetables may reduce ... of omega-6 rich oils may boost the risk of developing ... the diets of 8,085 people older than 65 who did ...
... 2007 The U.S. Pharmacopeia (USP) is pleased ... supplements for public notice and comment. ... monographs appeared in Pharmacopeial Forum (PF) 33(6), the ... Powdered Turmeric, Powdered Turmeric Extract, Curcuminoids, Curcuminoids Capsules, ...
... EDMONTON, Alberta, Nov. 15 Medical Services,International Inc. (Pink ... of the excellent independent test results obtained by regulatory,agencies ... interest in the dual,VScan test kit that detects HIV ... are known to be closely associated. It is very ...
Cached Medicine News:Health News:Rochester Medical Reports Record Fourth Quarter Sales and Record Year 2Health News:Rochester Medical Reports Record Fourth Quarter Sales and Record Year 3Health News:Rochester Medical Reports Record Fourth Quarter Sales and Record Year 4Health News:Rochester Medical Reports Record Fourth Quarter Sales and Record Year 5Health News:Rochester Medical Reports Record Fourth Quarter Sales and Record Year 6Health News:Rochester Medical Reports Record Fourth Quarter Sales and Record Year 7Health News:Rochester Medical Reports Record Fourth Quarter Sales and Record Year 8Health News:Nepstar Chain Drugstore (NPD) Greenshoe Fully Exercised 2Health News:NovaBay announces third quarter 2007 financial results 2Health News:NovaBay announces third quarter 2007 financial results 3Health News:NovaBay announces third quarter 2007 financial results 4Health News:NovaBay announces third quarter 2007 financial results 5Health News:NovaBay announces third quarter 2007 financial results 6Health News:NovaBay announces third quarter 2007 financial results 7Health News:Fish, Fruits, Veggies May Cut Dementia Risk 2Health News:USP announces 11 new proposed monographs for dietary supplements 2Health News:Medical Services Gets Significant Interest in Its Dual VScan Test Kit 2
Used for traversing and exploring urethral strictures. The malleable tip can be shaped to desired configuration. The proximal end is threaded to attach to standard followers. Supplied sterile in peel...
... Used retrograde to ... establish a Peel-Away ureteral ... The temporary protective Peel-Away ... away as the ureteroscope ...
The removable inflation/injection adapter allows the cystoscope to be removed after the catheter is in place. Supplied sterile in peel-open packages. Intended for one-time use....
Radiopaque markers are placed at the proximal and distal ends of the balloon. A special pin vise handle is included to stabilize the wire guide during introduction. Supplied sterile in peel-open pack...
Medicine Products: